CANCER RESEARCH AND BIOSTATISTICS

We beleive every cancer patient counts

aka CRAB   |   Seattle, WA   |  www.crab.org

Mission

Cancer Research And Biostatistics (CRAB) is a non-profit organization whose purpose is to help conquer cancer and other diseases through the application of biostatistical principles and innovative electronic data management methods.

Ruling year info

1998

CEO

Dr. Antje Hoering

Main address

1505 Westlake Ave N Ste 750

Seattle, WA 98109 USA

Show more contact info

EIN

91-1828539

NTEE code info

Cancer Research (H30)

IRS filing requirement

This organization is required to file an IRS Form 990 or 990-EZ.

Sign in or create an account to view Form(s) 990 for 2019, 2018 and 2017.
Register now

Programs and results

What we aim to solve

This profile needs more info.

If it is your nonprofit, add a problem overview.

Login and update

Our programs

SOURCE: Self-reported by organization

What are the organization's current programs, how do they measure success, and who do the programs serve?

SWOG Data Management Center

CRAB currently serves as the statistical center for the Southwest Oncology Group (SWOG), one of the largest adult cancer clinical trials organizations in the world. Funded primarily by the US Government, SWOG consists of some 4000 physicians and 300 institutions throughout the US and Canada, and since its inception in 1956 has enrolled over 150,000 patients.

CRAB was also responsible for coordinating one of the largest prevention trials ever attempted, The Selenium and Vitamin E Cancer Prevention Trial (SELECT).

CRAB is growing alliances with academic research institutions, pharmaceutical companies, and biotech companies in Seattle and around the US. Key partners include the Benaroya Research Institute, Virginia Mason Medical Center, Dendreon, Amgen, Salick Healthcare Systems, Ligand Pharmaceutical, the International Myeloma Foundation, the University Arkansas for Medical Sciences, the Pancreatic Cancer Research Team and the International Association for the Study of Lung Cancer.

CRAB has helped revolutionize the study of cancer in Japan, essentially spurring the growth of a new biostatistical industry. At the second annual Japanese/US Biostatistical Conference held in Seattle in September of 2004, Masanori Fukushima, MD, PhD, stated that as a result of this collaboration, Japanese clinical trial research and actual standard of patient care has improved.

CRAB leads the field in developing analytical methods to understand genomic and proteomic information gleaned from micro array technologies. The Myeloma Institute for Research and Therapy (MIRT) at the University of Arkansas has produced a large DNA array-based data set on patients with both multiple myeloma and with pre-cancerous conditions. As the statistical center for the MIRT, CRAB continues to have access to this burgeoning data set and continues to refine methods for analyzing these data. An analysis of these data sets was a primary focus of the first two annual Japanese/United States Biostatistics Workshops, first held in September, 2003, in Kobe, Japan and in September, 2004, in Seattle, Washington.

Training is an important focus for CRAB. The SWOG Clinical Trials Training Course and the SELECT Training Workshop are offered in the twice yearly. These two highly regarded workshops train field personnel how to manage treatment and prevention trials, respectively. An intensive, week-long Young Investigator?s Workshops is also offered each year. The intent is to mentor young physicians so that at the end of the workshop they have an actual research protocol ready for consideration in SWOG. These young physicians bring fresh ideas and vitality to SWOG and continue the tradition of seeking innovative cures for devastating diseases.

Population(s) Served

CRAB is the data center for SWOG, the largest cooperative group funded by the National Cancer Institute of the National Institutes of Health. CRAB gathers, validates and stores data from all SWOG studies and makes it available for analysis. Outcomes of SWOG trials set the standards of treatment around the world,

Population(s) Served
Adults

CRAB is the statistical center for MIRT, a leader in the research on causes of and treatment of Multiple Myeloma

Population(s) Served
Adults

The PCRT mission is to organize and accelerate the clinical development of new agents for the treatment of patients with pancreatic cancer. PCRT is an international collaborative organization formed by several world renowned institutions and researchers. PCRT conducts clinical trials in patients with pancreatic cancer, translating genomics research into prevention, diagnosis and treatment.

PCRT members include laboratory and clinical researchers in the U.S. and Europe, who share the passion to rapidly bring new advances to pancreatic cancer patients; PCRT provides the only coordinated effort in the world dedicated to swiftly translating research discoveries into new treatments and supportive care for patients with pancreatic cancer. All phases of clinical research are supported through PCRT.

To date, the PCRT consortium includes approximately 75 Oncology Clinicians, Surgeons and Researchers who are member-investigators of PCRT representing 45 research sites.

Population(s) Served
Adults

Where we work

Goals & Strategy

SOURCE: Self-reported by organization

Learn about the organization's key goals, strategies, capabilities, and progress.

Charting impact

Four powerful questions that require reflection about what really matters - results.

We remain focused on our mission by combining our oncology experience, expertise, and innovation in oncology clinical trial management to advance treatments and help conquer cancer.

As such, our goal is to deliver for our collaborators, key partners and clients: Trusted, high quality expertise, on time and on budget.

Key Partnerships: CRAB is the Data Center for the SWOG Statistical Center. Not only is SWOG by far our largest customer, it is through that relationship that our products, services and expertise have been honed.

CRAB has long standing partnerships with other research consortia which have provided opportunities to expand our expertise beyond clinical trials. We have refined and improved cancer staging for myeloma and lung cancer through our relationship with International Myeloma Foundation and International Association for the Study of Lung Cancer, respectively. Our ongoing work with the Myeloma Institute is rich with some of the earliest use of genomic analyses in the clinical trial arena, producing prognostic and predictive markers that continue to be refined for clinical use. Similarly, as the statistical center for the Pancreatic Cancer Research Team we are working with collaborators to combine translational data to improve clinical outcomes.

CRAB's Clinical Research Services (CRS) division looks to expand the number of key partnerships we have in place with research consortia as well as pharmaceutical clients. As we continue to build and leverage our oncology expertise, we believe our client-centric approach will help us to strengthen and expand our key research partnerships.

CRAB's CEO, Antje Hoering, is collaborating with a select number of executives to address significant, and often very similar, challenges related to the generation of grant revenue, research and development, collaborating with industry, and other institutional administrative matters. The Pacific Northwest Life Sciences Executive Forum was created to bring together executive level professionals from non-profit life sciences organizations in the Pacific Northwest to mutually discuss these shared challenges, share best practices, and determine areas for potential inter-institutional or regional collaboration.

Biostatistical Services. The design and analysis of a wide variety of oncology clinical trials constitutes the majority of our work. Trials range from Phase I single or multi -institution industry sponsored to Phase III multi-institutional cooperative group trials.

Clinical Trial Services. CRAB provides an efficient and seamless suite of clinical trial services from inception of the study to publication of the results. Our statisticians design studies such that the key questions can be answered unambiguously. They work with Data Monitors and Applications Developers to create an Electronic Data Capture system that will capture data necessary for the trial. Project managers oversee the entire process to assure the study is on time and on budget. Once the study is activated our Data Managers use this powerful EDC system to perform centralized monitoring of the data in real time, assuring the data are clean, complete and accurate through resolution of queries. Our approach to centralized data monitoring reduces the need for on-site clinical monitoring except in trials requiring FDA approval. Statisticians provide interim analyses, DSM reporting and support, final analyses and writing for publication.

Training. An important part of our service delivery is the training of professionals to confidently use our systems or understand our science.

CRAB has long enjoyed a successful partnership with SWOG and other key partnerships in clinical trial work, and looks forward to great collaborations in 2017.

For more information about CRAB, please see News and Events at the following link.
http://www.crab.org/NewsEvents.aspx

Financials

CANCER RESEARCH AND BIOSTATISTICS
lock

Unlock financial insights by subscribing to our monthly plan.

Subscribe

Unlock nonprofit financial insights that will help you make more informed decisions. Try our monthly plan today.

  • Analyze a variety of pre-calculated financial metrics
  • Access beautifully interactive analysis and comparison tools
  • Compare nonprofit financials to similar organizations

Want to see how you can enhance your nonprofit research and unlock more insights?
Learn more about GuideStar Pro.

Operations

The people, governance practices, and partners that make the organization tick.

lock

Connect with nonprofit leaders

Subscribe

Build relationships with key people who manage and lead nonprofit organizations with GuideStar Pro. Try a low commitment monthly plan today.

  • Analyze a variety of pre-calculated financial metrics
  • Access beautifully interactive analysis and comparison tools
  • Compare nonprofit financials to similar organizations

Want to see how you can enhance your nonprofit research and unlock more insights? Learn More about GuideStar Pro.

lock

Connect with nonprofit leaders

Subscribe

Build relationships with key people who manage and lead nonprofit organizations with GuideStar Pro. Try a low commitment monthly plan today.

  • Analyze a variety of pre-calculated financial metrics
  • Access beautifully interactive analysis and comparison tools
  • Compare nonprofit financials to similar organizations

Want to see how you can enhance your nonprofit research and unlock more insights? Learn More about GuideStar Pro.

CANCER RESEARCH AND BIOSTATISTICS

Board of directors
as of 3/11/2021
SOURCE: Self-reported by organization
Board chair

Dr. John Crowley

CRAB

Term: 1998 - 2020

David Gray

John Crowley

CRAB

Gary Goodman

Swedish Hospital Tumor Institute

Frank Curci

Ater Wynn, LLP

Cynthia Adkins

Adkins, Plant, Elvins & Black, PLLC

Michael LeBlanc

Fred Hutchinson Cancer Research Center

Kari Knudson

The Commerce Bank of Washington

Patrick Heagerty

University of Washington

Angie Schroeder

Fred Hutchinson Cancer Research Center

Board leadership practices

SOURCE: Self-reported by organization

GuideStar worked with BoardSource, the national leader in nonprofit board leadership and governance, to create this section.

  • Board orientation and education
    Does the board conduct a formal orientation for new board members and require all board members to sign a written agreement regarding their roles, responsibilities, and expectations? No
  • CEO oversight
    Has the board conducted a formal, written assessment of the chief executive within the past year ? Yes
  • Ethics and transparency
    Have the board and senior staff reviewed the conflict-of-interest policy and completed and signed disclosure statements in the past year? Yes
  • Board composition
    Does the board ensure an inclusive board member recruitment process that results in diversity of thought and leadership? Yes
  • Board performance
    Has the board conducted a formal, written self-assessment of its performance within the past three years? No